Lv64
1700 积分 2024-04-15 加入
Lessons learned from independent central review
18小时前
待确认
Elements of cancer immunity and the cancer–immune set point
6天前
已完结
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR
7天前
已完结
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer
1个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
1个月前
已完结
Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis
1个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
1个月前
已完结
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
2个月前
已完结
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
2个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
